Quest Diagnostics Incorporated (DGX)
NYSE: DGX · Real-Time Price · USD
227.86
-0.04 (-0.02%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Quest Diagnostics Stock Forecast
Stock Price Forecast
According to 18 analysts polled by S&P Global, Quest Diagnostics stock has a consensus rating of "Buy" and an average price target of $239.38. The average 1-year stock price forecast is 5.06% higher than the current stock price, while the lowest is $204 (-10.47%) and the highest is $265 (+16.30%).
Price Target: $239.38 (+5.06%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Quest Diagnostics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 8 | 9 | 9 | 9 | 8 | 9 |
| Sell | 1 | 0 | 0 | 0 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 18 | 18 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Reiterates $265 | Buy | Reiterates | $265 | +16.30% | Jul 24, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $226 → $260 | Buy | Maintains | $226 → $260 | +14.11% | Jul 24, 2026 |
| UBS | UBS | Hold Maintains $220 → $232 | Hold | Maintains | $220 → $232 | +1.82% | Jul 24, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Maintains $235 → $260 | Buy | Maintains | $235 → $260 | +14.11% | Jul 24, 2026 |
| Truist Financial | Truist Financial | Hold Maintains $225 → $250 | Hold | Maintains | $225 → $250 | +9.72% | Jul 24, 2026 |
Financial Forecast
Revenue This Year
11.85B
from 11.04B
Increased by 7.41%
Revenue Next Year
12.37B
from 11.85B
Increased by 4.36%
EPS This Year
10.77
from 9.85
Increased by 9.32%
EPS Next Year
11.67
from 10.77
Increased by 8.37%
EPS and Forward PE are based on non-GAAP adjusted numbers.